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Vitamin D and
Cardiovascular Disease
Time for Large Randomized Trials*
Carlos A. Camargo, JR, MD, DRPH
Boston, Massachusetts
Vitamin D is a hormone of critical importance to calcium
homeostasis and bone health (1). Although widely regarded
as a vitamin, a more accurate term is “conditional vitamin,”
in that vitamin D is required in the diet only when the skin
does not make enough through the action of ultraviolet B
radiation from the sun. At higher latitudes (e.g., most of the
United States, all of Canada and Europe, southern Austra-
lia, and all of New Zealand), ultraviolet B exposure drops
dramatically during autumn and winter (2). Although it is
certainly possible to produce and store sufficient vitamin D
after abundant sunlight exposure in spring and summer,
indoor life-styles and sun avoidance campaigns have de-
creased such exposure and led many to require ingestion of
this unique hormone/vitamin.
See page 1433
Over the past decade, a growing body of evidence
suggests that the health effects of vitamin D extend beyond
rickets and bone health (2). Although it would be preferable
to know local (even intracellular) levels of the active hor-
mone (i.e., 1,25-dihydroxyvitamin D), circulating levels of
the precursor, 25-hydroxyvitamin D (25-OHD), remain the
best available method of measuring overall vitamin D status.
The recommended level of serum 25-OHD is highly
controversial, with some recommending a level of 20 ng/ml
or higher (3) while others recommend a level of at least 30
ng/ml (4,5) or much higher (6). However, using either the
20 or 30 ng/ml threshold, national studies clearly document
low serum 25-OHD levels for a substantial segment of the
U.S. population, particularly among racial and ethnic mi-
norities (7).
Of particular interest to cardiovascular researchers and
clinicians is growing evidence of a link between low vitamin
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Hospital Center for D-Receptor Activation Research.D and increased risk for cardiovascular disease (CVD) (8).
lthough this may seem like a recent development, the
rigins of this hypothesis actually go back a few decades. In
981 Scragg (9) drew on ecological studies of variations in
VD by season, latitude, and altitude and published a
ypothesis that sunlight and vitamin D may protect against
VD. In 1990, Scragg et al. (10) reported a population-
ased case-control study from New Zealand that found a
trong inverse association between plasma 25-OHD level
nd risk for myocardial infarction (10). Over the past 5
ears, there has been renewed interest in this hypothesis,
ith supportive evidence from several large prospective
ohort studies (11), including analyses that focused on older
dults (12). Indeed, the original hypothesis about myocar-
ial infarction has now expanded to include atherosclerosis,
eart failure, stroke, and several cardiometabolic disorders
e.g., hypertension, diabetes). Although an explanation for
hese diverse “effects” remains unclear, it undoubtedly in-
olves multiple mechanisms. The growing enthusiasm for
itamin D deficiency as an important, common, and easily
reatable CVD risk factor (8) has been offset recently by
kepticism about vitamin D as a panacea, a view reflected in
2011 report from the Institute of Medicine (3). In brief,
keptics wonder if vitamin D status is simply a marker of
eneral health. In other words, do healthier people tend to
pend more time outside, resulting in more ultraviolet B
xposure and thus higher 25-OHD levels? In such a
cenario, confounding by better baseline health (or outdoor
ctivity) would account for the positive findings in recent
pidemiologic studies. If the association between vitamin D
nd CVD is truly confounded in this manner, the initiation
f vitamin D supplements might yield little (if any) impact
n CVD risk.
In this issue of the Journal, Kestenbaum et al. (13)
xamine the associations of 25-OHD, parathyroid hormone
PTH), and incident CVD in the Cardiovascular Health
tudy. In 2,312 older adults who were free of CVD at
aseline, 17% had baseline 25-OHD levels 15 ng/ml, and
5% had baseline PTH levels 65 pg/ml. In brief, the
nvestigators found that baseline levels of 25-OHD were
nversely associated with risk for myocardial infarction and
ll-cause mortality, while PTH excess was associated with
eart failure. Although statistical power was limited, they
ound no evidence of an interaction between 25-OHD and
TH levels and cardiovascular events. These findings sup-
ort those who believe that low vitamin D is a modifiable
isk factor for at least some types of CVD, such as
yocardial infarction, and also raise the possibility that
itamin D and PTH might influence CVD risk through
ivergent pathways, at least in this population of older
dults without baseline CVD and 1% baseline use of
itamin D supplements.
With regard to the confounding, the investigators had
ata on all of the traditional CVD risk factors, including
hysical activity, and multivariate analyses adjusted for these
1443JACC Vol. 58, No. 14, 2011 Camargo, Jr
September 27, 2011:1442–4 Vitamin D and CVDfactors. Although it remains possible that residual con-
founding is responsible for the observed associations, it is
also possible that an observed association is both causal and
confounded. In other words, even a demonstrably con-
founded association might be true. Although multivariate
analysis would begin to address confounding, other meth-
odologic limitations (e.g., the use of a single measure to look
at 14-year outcomes) probably obscured real associations.
The final odds ratio reflects a complex mixture of causality,
bias and confounding. Notwithstanding these familiar epi-
demiologic challenges, the findings are generally consistent
with those of prior studies. For example, the all-cause
mortality finding (a 9% increase for every 10 ng/ml decrease
in 25-OHD) matches a meta-analysis of bone health
randomized controlled trials (RCTs) comparing vitamin D
with placebo, in which vitamin D supplementation yielded
a 7% reduction in all-cause mortality (14).
The investigators’ suggestion that vitamin D and PTH
may affect CVD risk through divergent pathways requires
further study. Although it is likely that these hormones have
more (or less) impact on specific outcomes, PTH represents
an endogenous biologic marker of inadequate vitamin D; it
seems highly likely that there would be some overlap.
Although it is tempting to conclude that PTH is uniquely
associated with heart failure, other studies suggest that
vitamin D plays an important role in the pathogenesis and
clinical course of heart failure (15,16). It is possible that
PTH plays a predominant role in some populations, but I
doubt that this is an all-or-none phenomenon. Further
epidemiologic studies are needed to clarify this issue.
More important, the field needs insights from 2 other
types of research: 1) translational research to improve
understanding of potential mechanisms for the emerging
epidemiologic associations; and 2) large, population-based
RCTs to formally test causality in humans. Already, 2 such
trials are under way (Table 1): the ViDA (Vitamin D
Assessment) trial in New Zealand and the VITAL (Vitamin
D and Omega-3 Trial) in the United States. The 2 RCTs
are sufficiently different that they should provide comple-
mentary answers to the major question, Does the initiation
of vitamin D supplementation prevent CVD? The design
Large, Population-Based, Randomized, Double-Blind, Placebo-Contron the Health Effects of Vit min D Supplementation (as of AugusTable 1 Larg , Population-Based, Randomized, Doubl -Blind, Plon the Health Effects of Vitamin D Supplementation (a
ViDA
Country New Zealand
Principal investigator(s) Scragg and Camargo
Target sample size 5,100
Age range 50–84 yrs (both men and women)
Vitamin D3 intervention 100,000 IU/month (about 3,300 IU/day); subjects also
an extra 100,000 IU at the start of the trial and ever
Primary outcomes CVD, infection, fractures
Year enrollment started 2011
Expected year of results 2017
Trial registration ACTRN12611000402943CVD  cardiovascular disease; ViDA  Vitamin D Assessment trial; VITAL  Vitamin D and Omega-3 Triaand implementation of additional population-based RCTs
would help address the impact of other vitamin D regimens
in different populations.
Unfortunately, these trials will take several years to
complete. In the meantime, in the absence of RCT evi-
dence, it is difficult to draw conclusions about the cardio-
vascular benefits of vitamin D supplementation (3). Even
for those at lower 25-OHD levels, there is controversy
about the 25-OHD target for optimal general health, with
several discordant recommendations in the published re-
search (3–6). On the basis of my review of the available
data, I believe that the optimal 25-OHD level for most
health problems will be around 40 ng/ml (100 nmol/l), with
relatively small differences found in the range of 35 to 50
ng/ml. I also submit that it will be easier to demonstrate
benefit by elevating a person’s 25-OHD from, for example,
10 to 20 ng/ml, compared to elevating another person’s
25-OHD from 40 to 50 ng/ml; baseline levels of 25-OHD
have to matter. Although this may seem like a common-
sense observation, the role of baseline vitamin status in
RCTs continues to receive inadequate attention in scientific
circles (17). Last, given the many factors that affect vitamin
D status (e.g., latitude, season, sunlight exposure, skin color,
obesity, genetics), the search for a “one-size-fits-all” regi-
men seems misguided. Although RCTs need to test specific
doses because of the ethical challenge of testing baseline
25-OHD and then assigning someone with established
(albeit asymptomatic) vitamin D deficiency to placebo, it is
unclear why supplementation of individual patients should
be restricted to a fixed regimen.
In summary, for those who believe that the inverse
association between vitamin D and CVD risk is probably
causal, and that the association will prove modifiable, the
next steps are clear: widespread serum 25-OHD testing and
vitamin D supplementation to achieve a specific 25-OHD
target. For those who are more skeptical of epidemiologic
associations, who have concerns about adding unjustified
costs to an already burdened health system, or who worry
that supplementation may cause unintended harm—as has
happened with antioxidant interventions (18)—the next
steps are equally clear: the imperative of completing large
Trials)o-Controlled Trials
August 2011)
VITAL
United States
Manson and Buring
20,000
Men: 50 yrs; women: 55 yrs
ven
mn
2,000 IU/day; part of a 2  2 factorial trial in which the other intervention
is 1 g/day of specific omega-3 fatty acids
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2011
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Vitamin D and CVD September 27, 2011:1442–4RCTs to justify changes in clinical practice and health
policy. In a few years, ViDA and VITAL will begin to shed
a light on this important and controversial issue.
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